Clinical Trial

The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated December 2, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The Department of Gastroenterology plans to conduct a randomized controlled study on the efficacy analysis of hyperbaric oxygen-assisted treatment for acute severe ulcerative colitis and refractory inflammatory bowel disease. The research design is a randomized, controlled study. The objective is to compare the clinical remission rate, clinical response rate, endoscopic remission rate, and endoscopic response rate between patients with acute severe ulcerative colitis (ASUC) and refractory inflammatory bowel disease (IBD) treated with hyperbaric oxygen therapy (HBOT) as an adjuvant and those treated with standard treatment regimens. This study aims to provide clear evidence for the use of HBOT as an adjuvant treatment for ASUC and refractory IBD.
Trial Details
NCT Number NCT07257588
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions Ulcerative Colitis
Enrollment 44 participants
Start Date 2024-09-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-02